Logo Veracyte, Inc. - VCYT 29.19 USD

P/E
69.49
EPS
0.41
P/B
1.87
ROE
2.86
Beta
2.15
Target Price
40.50 USD

29.187 USD

29.187 USD

Daily: +2.45%
Key Metrics

P/E: 69.49

EPS: 0.41

Book Value: 15.26

Price to Book: 1.87

Debt/Equity: 4.23

% Insiders: 0.488%

Growth

Revenue Growth: 0.18%

Estimates

Forward P/E: 71.23

Forward EPS: 0.40

Target Mean Price: 40.50

 Logo About Veracyte, Inc. - (VCYT)

Country: United States

Sector: Health Care

Website: http://www.veracyte.com

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) VCYT
FRA (Germany) 12V.F

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion